In a single-center retrospective analysis, 87 patients with newly diagnosed FLT3-mutated AML were treated with either triplet therapy (n = 27) or doublet therapy with a lower-intensity therapy plus a FLT3 inhibitor, without venetoclax (n = 60) [55]. This evidence concerns the gene FLT3 and acute myeloid leukemia.